Bristol Financials

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Understanding current and past Bristol Myers Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. Bristol Myers Total Assets Per Share are fairly stable at the moment as compared to the past year. Bristol Myers reported Total Assets Per Share of 57.73 in 2019. Net Current Assets as percentage of Total Assets is likely to grow to 13.00 in 2020, whereas Net Income Per Employee is likely to drop slightly above 106.8 K in 2020. Use fundamental data analysis to double-check all available reported financial drivers of Bristol Myers Squibb to find out if markets are presently mispricing the company. We were able to interpolate and analyze data for thirty-eight available fundamental indicators for Bristol Myers Squibb, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Bristol Myers Squibb financials, including its price to earning, book value per share, current liabilities, as well as the relationship between the net income and beta . Given that Bristol Myers Squibb has a price to earning of 113.27 X, we suggest you to validate Bristol Myers Squibb prevailing market performance to make sure the company can sustain itself down the road. Use Bristol Myers to protect your portfolios against small markets fluctuations. The stock experiences a somewhat bearish sentiment, but market may correct it shortly. Check odds of Bristol Myers to be traded at $55.71 in 30 days.

Search Fundamentals

 
Refresh
With this module, you can analyze Bristol financials for your investing period. You should be able to track the changes in Bristol Myers individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
34%34%

Chance of Financial Distress

Bristol Myers Squibb has less than 34 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Bristol Myers stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info

Bristol Myers Company Summary

Bristol Myers competes with Gilead Sciences, Merck, Grifols S, Johnson Johnson, and GlaxoSmithKline PLC. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people.
Foreign Associate  Mexico
Specialization
Healthcare, Drug Manufacturers - General
InstrumentUSA Stock View All
ExchangeBATS Exchange
CIK Number0000014272
ISINUS1101221083
CUSIP110122108
RegionNorth America
LocationNew York; U.S.A
Business Address430 E 29th
SectorHealthcare
IndustryDrug Manufacturers?General
BenchmarkDOW
Websitewww.bms.com
Phone212 546 4020
Related EntityBMY
CurrencyUSD - US Dollar

Bristol Myers Key Financial Ratios

Bristol Myers Key Balance Sheet Accounts

2014201520162017201820192020 (projected)
Inventories1.56 B1.22 B1.24 B1.17 B1.2 B4.29 B4.63 B
Receivables2.32 B3.16 B4.01 B5.09 B5.35 B7.68 B8.29 B
Accounts Payable2.49 B1.56 B1.66 B2.25 B1.89 B2.44 B2.56 B
Total Assets33.75 B31.75 B33.71 B33.55 B34.99 B129.94 B140.2 B
Current Assets14.61 B10.41 B13.7 B14.85 B17.72 B29.35 B24.48 B
Assets Non Current19.14 B21.33 B20 B18.7 B17.27 B100.59 B108.53 B
Cash and Equivalents5.57 B2.38 B4.24 B5.42 B6.91 B12.35 B13.32 B
Total Debt7.83 B6.69 B6.71 B7.96 B7.35 B46.73 B50.42 B
Debt Current590 M139 M992 M987 M1.7 B3.35 B3.61 B
Debt Non Current7.24 B6.55 B5.72 B6.97 B5.65 B43.39 B46.81 B
Deferred Revenue1.52 B1.94 B1.59 B1.31 B537 M483.3 M496.02 M
Shareholders Equity14.85 B14.27 B16.18 B11.74 B14.03 B51.6 B55.67 B
Inventory1.56 B1.22 B1.24 B1.17 B1.2 B4.29 B4.63 B
Investments6.27 B6.54 B4.83 B3.87 B3.62 B3.81 B3.97 B
Investments Current1.86 B1.89 B2.11 B1.39 B1.85 B3.05 B2.67 B
Total Liabilities18.77 B17.32 B17.36 B21.7 B20.86 B78.25 B84.42 B
Current Liabilities8.46 B8.02 B8.84 B9.56 B10.65 B18.3 B15.18 B
Tax Assets2.56 B2.84 B3 B1.61 B815 M510 M523.42 M
Tax Liabilities822 M1.31 B1.12 B3.78 B19 M6.45 B6.96 B

Bristol Myers Key Income Statement Accounts

2014201520162017201820192020 (projected)
Direct Expenses3.93 B3.91 B4.95 B6.07 B6.55 B8.08 B6.51 B
Consolidated Income2.03 B1.63 B4.51 B975 M4.95 B3.46 B3.52 B
Cost of Revenue3.93 B3.91 B4.97 B6.01 B6.47 B8.08 B7.34 B
Gross Profit11.95 B12.65 B14.46 B14.76 B16.09 B18.07 B17.73 B
Net Income2 B1.56 B4.46 B1.01 B4.92 B3.44 B3.32 B
Operating Expenses9.57 B10.57 B8.54 B9.63 B10.13 B13.09 B12.5 B
Operating Income2.38 B2.08 B5.92 B5.13 B5.97 B4.97 B4.52 B
Revenues15.88 B16.56 B19.43 B20.78 B22.56 B26.14 B25.07 B
Income Tax Expense352 M446 M1.41 B4.16 B1.02 B1.51 B1.51 B

Bristol Myers Key Cash Accounts

2014201520162017201820192020 (projected)
Capital Expenditure(526 M)(820 M)(1.22 B)(1.05 B)(951 M)(836 M)(902 M)
Depreciation Amortization and Accretion467 M376 M382 M789 M637 M1.75 B1.88 B
Net Cash Flow or Change in Cash and Cash Equivalents1.99 B(3.19 B)1.85 B1.18 B1.49 B5.91 B6.38 B
Net Cash Flow Business Acquisitions and Disposals3.37 B(403 M)975 M10 M3 M(8.78 B)(9.01 B)
Issuance Purchase of Equity Shares131 M288 M(231 M)(2.47 B)(320 M)(7.3 B)(7.49 B)
Issuance Repayment of Debt Securities(432 M)(1.14 B)110 M991 M(548 M)17.65 B19.05 B
Payment of Dividends and Other Cash Distributions(2.4 B)(2.48 B)(2.55 B)(2.58 B)(2.61 B)(2.68 B)(2.89 B)
Net Cash Flow from Financing(2.44 B)(3.62 B)(2.65 B)(4.08 B)(3.54 B)7.62 B8.22 B
Net Cash Flow from Investing1.22 B(1.57 B)1.48 B(66 M)(874 M)(9.77 B)(10.03 B)
Net Cash Flow Investment Acquisitions and Disposals(1.62 B)(349 M)1.72 B979 M74 M(152 M)(164 M)
Net Cash Flow from Operations3.15 B2.1 B3.06 B5.28 B5.94 B8.07 B6.96 B
Effect of Exchange Rate Changes on Cash58 M(95 M)(33 M)52 M(41 M)(9 M)(9.24 M)
Share Based Compensation213 M235 M205 M199 M221 M441 M358.21 M

Bristol Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.
Bristol Myers Squibb is rated fourth in retained earnings category among related companies. It is rated below average in net income category among related companies making up about  0.03  of Net Income per Retained Earnings. The ratio of Retained Earnings to Net Income for Bristol Myers Squibb is roughly  38.80 . Bristol Myers Net Income is fairly stable at the moment as compared to the past year. Bristol Myers reported Net Income of 3.44 Billion in 2019

Bristol Myers Squibb Systematic Risk

The output start index for this execution was nine with a total number of output elements of fifty-two. The Beta measures systematic risk based on how returns on Bristol Myers Squibb correlated with the market. If Beta is less than 0 Bristol Myers generally moves in the opposite direction as compared to the market. If Bristol Myers Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bristol Myers Squibb is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bristol Myers is generally in the same direction as the market. If Beta > 1 Bristol Myers moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Bristol Myers Financials

What exactly are Bristol Myers Financials? Typically, a company's financial statements are the reports that show the financial position of the company. There are three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Potential Bristol Myers investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B

Bristol Myers Thematic Clasifications

Bristol Myers Squibb is part of several thematic ideas from Pharmaceutical Products to Compulsion. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Pharmaceutical Products Idea
Pharmaceutical ProductsView
Compulsion Idea
CompulsionView

Bristol Myers July 13, 2020 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Bristol Myers help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bristol Myers Squibb. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bristol Myers Squibb based on widely used predictive technical indicators. In general, we focus on analyzing Bristol Myers stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bristol Myers's daily price indicators and compare them against related drivers.
Downside Deviation1.54
Information Ratio(0.11)
Maximum Drawdown8.37
Value At Risk(1.90)
Potential Upside2.13
Continue to Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page